Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
Open accessThe DOI matches its Crossref record; 84 of the 115 references it cites were found in a registry or an index.
Abstract
Summary: Bispecific T-cell engagers (BiTEs) redirect endogenous T-cell populations to cells expressing tumour-associated antigens to induce tumour cell killing. This inherently relies upon a cytotoxic T-cell population that is able to be recruited. In many cancers, immune checkpoints and other immunosuppressive factors in the tumour microenvironment lead to a population of anergic T-cells which cannot be redirected to tumour killing and thus impede the efficacy of BiTE therapy. Furthermore, there is evidence that BiTE therapy itself can increase immune checkpoint expression, and this is thought to be a major escape mechanism for the BiTE therapy blinatumomab. To overcome these inadequate T-cell responses, BiTEs may be combined with checkpoint inhibitors, chemotherapy, costimulatory molecules or oncolytic viruses. Study of these combinations is needed to expand the use of BiTEs in solid malignancies. This review covers the rationale, preclinical evidence and any clinical trials for these combination therapies and a few other less-studied combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. The cancer-immunity cycle (adapted from [1]). Tumour cell death leads to release of antigens which are taken up by antigen presenting cells (APCs). These travel to lymph nodes and activate lymphocytes, including cytotoxic T-lymphocytes (CTLs) which travel to the tumour site in the circulation and to the infiltrate by extravasation. These infiltrating CTLs cause tumour cell lysis which releases further tumour antigens that perpetuate the cycle. Produced using biorender.com.](https://figures.cochat.ai/paper-figures/a0915283d9de4093ad444cf66d7c73d6/combination-therapies-for-the-optimisation-of-bispecific-t-cell-engagers-in-figure-1.jpg)
![Figure 2. Mechanism of BiTE-mediated tumour lysis. BiTEs form an immunological synapse between T-cells and TAA presenting cells by binding CD3 (most commonly, but other T-cell-associated targets such as CD28 or 4-1BB exist, as discussed below) and a TAA of choice. Binding of both arms of the BiTE activates the T-cell and leads to degranulation of cytotoxic perforins and granzyme B across the immunological synapse, leading to tumour cell lysis [2]. As the BiTE depicted directly targets CD3 on T-cells, activation occurs in a TCR-independent fashion that results in activation of a polyclonal population of T-cells. Crucially, BiTE-mediated tumour lysis would also perpetuate the cancer-immunity (depicted in Figure 1) because activated T-cells secrete immune activating cytokines, and tumour cell lysis leads to antigen release, uptake by APCs and subsequent immune activation (Figure 1; steps 4 and 1). Produced using biorender.com.](https://figures.cochat.ai/paper-figures/c1a8a8dbbe5a4995bd7b15254fc02f6a/combination-therapies-for-the-optimisation-of-bispecific-t-cell-engagers-in-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By linking two distinct single-chain variable fragments (scFvs), BiTEs target both a tumor-associated antigen and a TCR component necessary for T-cell activation, typically CD3 [85].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 2×
“The cancer-immunity cycle (adapted from [1]).”
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“The ABL1 944C→T (Thr315Ile) mutation is a known driver of TKI resistance in haematological malignancies [50].”
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960 · cited 1×
“phase 3 trial for advanced melanoma despite promising preclinical data [80].”
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103485 · Cited by 924
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 831
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · cited 1×
“Moreover, many factors in the TME contribute to immunosuppression via a common pathway of PD-L1 upregulation [59], but if PD-L1 is used as the TAA arm of the BiTE, this normally detrimental effect now simply increases the available targets for PD-L1 targeted BiTEs to bind [60].”
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Press, M. F., Cordon‐Cardo, C., & Slamon, D. J. (1990) · PubMed · Cited by 638
Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Foà, R., Bassan, R., Vitale, A., Elia, L., Piciocchi, A., Puzzolo, M.-C., Canichella, M., Viero, P., Ferrara, F., Lunghi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016272 · Cited by 522
Bispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015) · Immunology & Cell Biology · doi:10.1038/icb.2014.93 · Cited by 466
Lee, S.-J., Jang, B.-C., Lee, S.-W., Yang, Y.-I., Suh, S.-I., Park, Y.-M., Oh, S., Shin, J.-G., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446
Ibrutinib treatment improves T cell number and function in CLL patients
Long, M., Beckwith, K., Do, P., Mundy, B. L., Gordon, A., Lehman, A. M., Maddocks, K. J., Cheney, C., Jones, J. A., Flynn, J. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89756 · Cited by 388
Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1696 · Cited by 345
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0180-3 · Cited by 336
Weinkove, R., George, P., Dasyam, N., & McLellan, A. D. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1049 · Cited by 324
Duell, J., Dittrich, M., Bedke, T., Mueller, T., Eisele, F., Rosenwald, A., Rasche, L., Hartmann, E., Dandekar, T., Einsele, H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.41 · Cited by 278
Wu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez-Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 259
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Lichtenegger, F. S., Köhnke, T., Vick, B., Jeremias, I., Metzeler, K. H., Altmann, T., et al. (2016) · Leukemia · doi:10.1038/leu.2015.214 · Cited by 253
Jabbour, E., Short, N. J., Jain, N., Huang, X., Montalban-Bravo, G., Banerjee, P., Rezvani, K., Jiang, X., Kim, K. H., Kanagal-Shamanna, R., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00319-2 · Cited by 250
CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
Slaney, C. Y., Wang, P., Darcy, P. K., & Kershaw, M. H. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0297 · Cited by 228
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
Zhai, L., Bell, A., Ladomersky, E., Lauing, K. L., Bollu, L., Sosman, J. A., Zhang, B., Wu, J. D., Miller, S. D., Meeks, J. J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01185 · Cited by 222
Mastelic-Gavillet, B., Navarro Rodrigo, B., Décombaz, L., Wang, H., Ercolano, G., Ahmed, R., Lozano, L. E., Ianaro, A., Derré, L., Valerio, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0719-5 · Cited by 216
The dual role of thymidine phosphorylase in cancer development and chemotherapy
Bronckaers, A., Gago, F., Balzarini, J., & Liekens, S. (2009) · Medicinal Research Reviews · doi:10.1002/med.20159 · Cited by 206
Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
Sanmamed, M. F., & Chen, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000061 · Cited by 178
Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
Jhawar, S. R., Thandoni, A., Bommareddy, P. K., Hassan, S., Kohlhapp, F. J., Goyal, S., Schenkel, J. M., Silk, A. W., & Zloza, A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00202 · Cited by 178
Köhnke, T., Krupka, C., Tischer, J., Knösel, T., & Subklewe, M. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0213-6 · Cited by 174
Feucht, J., Kayser, S., Gorodezki, D., Hamieh, M., Döring, M., Blaeschke, F., Schlegel, P., Bösmüller, H., Quintanilla-Fend, L., Ebinger, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12357 · Cited by 171
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Middelburg, J., Kemper, K., Engelberts, P., Labrijn, A. F., Schuurman, J., & van Hall, T. (2021) · Cancers · doi:10.3390/cancers13020287 · Cited by 170
Tabernero, J., Melero, I., Ros, W., Argiles, G., Marabelle, A., Rodriguez-Ruiz, M. E., Albanell, J., Calvo, E., Moreno, V., Cleary, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3002 · Cited by 170
Skokos, D., Waite, J. C., Haber, L., Crawford, A., Hermann, A., Ullman, E., Slim, R. M., Godin, S., Ajithdoss, D. K., Ye, X., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7888 · Cited by 160
Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
Junttila, T. T., Li, J., Johnston, J., Hristopoulos, M., Clark, R., Ellerman, D., Wang, B.-E., Li, Y., Mathieu, M., Li, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3622-t · Cited by 156
de Sostoa, J., Fajardo, C. A., Moreno, R., Ramos, M. D., Farrera-Sal, M., & Alemany, R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0505-4 · Cited by 156
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Freedman, J. D., Hagel, J., Scott, E. M., Psallidas, I., Gupta, A., Spiers, L., Miller, P. F., Kanellakis, N. I., Ashfield, R., Fisher, K. D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707567 · Cited by 138
Design and application of oncolytic viruses for cancer immunotherapy
Ylösmäki, E., & Cerullo, V. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.11.016 · Cited by 136
Overcoming the challenges associated with CD3+ T-cell redirection in cancer
Singh, A. K., Dees, S., & Grewal, I. S. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01225-5 · Cited by 122
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
Heidbuechel, J. P. W., & Engeland, C. E. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01075-5 · Cited by 120
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
Speck, T., Heidbuechel, J. P. W., Veinalde, R., Jaeger, D., Kalle, C. V., Ball, C. R., Ungerechts, G., & Engeland, C. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2651 · Cited by 119
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Trinklein, N. D., Pham, D. T., Schellenberger, U., Buelow, B. D., Boudreau, A. A., Choudhry, P., Clarke, S., Dang, K. H., Harris, K. E., Iyer, S., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1574521 · Cited by 119
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
Nagorsen, D., Bargou, R. C., Rüttinger, D., Kufer, P., Baeuerle, P. A., & Zugmaier, G. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902943077 · Cited by 106
Osada, T., Patel, S. P., Hammond, S. A., Osada, K., Morse, M. A., & Lyerly, H. K. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1671-y · Cited by 101
Correnti, C., Laszlo, G. S., de van der Schueren, W., Godwin, C. D., Bandaranayake, A. D., Busch, M. A., Gudgeon, C. J., Bates, O. M., Olson, J. M., Mehlin, C., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0014-3 · Cited by 89
Chang, C.-H., Wang, Y., Li, R., Rossi, D. L., Liu, D., Rossi, E. A., Cardillo, T. M., & Goldenberg, D. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3431 · Cited by 86
Solid Tumor Immunotherapy with T Cell Engager‐Armed Oncolytic Viruses
Scott, E. M., Duffy, M. R., Freedman, J. D., Fisher, K. D., & Seymour, L. W. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700187 · Cited by 80
Kauer, J., Hörner, S., Osburg, L., Müller, S., Märklin, M., Heitmann, J. S., Zekri, L., Rammensee, H., Salih, H. R., & Jung, G. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000621 · Cited by 75
Advani, A. S., Moseley, A. B., O’Dwyer, K. M., Wood, B. L., Park, J. H., Wieduwilt, M. J., Jeyakumar, D., Yaghmour, G., Atallah, E. L., Gerds, A. T., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008216 · Cited by 75
Mathur, D., Root, A. R., Bugaj‐Gaweda, B., Bisulco, S., Tan, X., Fang, W., Kearney, J. C., Lucas, J., Guffroy, M., Golas, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3275 · Cited by 70
Khalique, H., Baugh, R. T., Dyer, A., Scott, E. M., Frost, S., Larkin, S. J., Lei-Rossmann, J., & Seymour, L. W. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001292 · Cited by 62
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia
Brauchle, B., Goldstein, R., Karbowski, C. M., Henn, A., Li, C.-M., Bücklein, V., Krupka, C., Boyle, M. C., Koppikar, P., Haubner, S., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1093 · Cited by 61
Sam, J., Colombetti, S., Fauti, T., Roller, A., Biehl, M., Fahrni, L., Nicolini, V., Perro, M., Nayak, T. K., Bommer, E., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.575737 · Cited by 61
Groeneveldt, C., Kinderman, P., van den Wollenberg, D. J. M., van den Oever, R. L., Middelburg, J., Mustafa, D. A. M., Hoeben, R. C., van der Burg, S. H., van Hall, T., & van Montfoort, N. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001191 · Cited by 59
Stein, A. S., Franklin, J. L., Chia, V. M., Arrindell, D., Kormany, W. N., Wright, J., Parson, M., Amouzadeh, H. R., Choudhry, J., & Joseph, G. L. (2018) · Drug Safety · doi:10.1007/s40264-018-0760-1 · Cited by 53
Chiu, D., Tavaré, R., Haber, L., Aina, O. H., Vazzana, K., Ram, P., Danton, M. A., Finney, J., Jalal, S., Krueger, P., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0518 · Cited by 53
Webster, J. A., Luskin, M. R., Prince, G. T., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111845 · Cited by 50
Zhang, P., Shi, B., Gao, H., Jiang, H., Kong, J., Yan, J., Pan, X., Li, K., Zhang, P., Yao, M., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1497-4 · Cited by 49
Hornig, N., Kermer, V., Frey, K., Diebolder, P., Kontermann, R. E., & Müller, D. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182594387 · Cited by 48
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults
Saleh, K., Fernández, A., & Pasquier, F. (2022) · Cancers · doi:10.3390/cancers14071805 · Cited by 45
Shen, Y., Eng, J. S., Fajardo, F., Liang, L., Li, C., Collins, P. J., Tedesco, D., & Nolan-Stevaux, O. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004348 · Cited by 41
Wathikthinnakon, M., Luangwattananun, P., Sawasdee, N., Chiawpanit, C., Lee, V. S., Nimmanpipug, P., Tragoolpua, Y., Rotarayanont, S., Sangsuwannukul, T., Phanthaphol, N., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09964-6 · Cited by 40
Yeku, O., Rao, T. D., Laster, I., Kononenko, A. P., Purdon, T. J., Wang, P., Cui, Z., Liu, H., Brentjens, R. J., & Spriggs, D. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663379 · Cited by 39
Jabbour, E. J., Sasaki, K., Short, N. J., Ravandi, F., Huang, X., Khoury, J. D., Kanagal‐Shamanna, R., Jorgensen, J. L., Khouri, I. F., Kebriaei, P., et al. (2021) · Cancer · doi:10.1002/cncr.33469 · Cited by 38
Middleton, M. R., Höeller, C., Michielin, O. A., Robert, C., Caramella, C., Öhrling, K., & Hauschild, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0994-4 · Cited by 34
Self-citationHong, R., Zhou, Y., Tian, X., Wang, L., & Wu, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.10.008 · Cited by 30
Sam, J., Colombetti, S., Fauti, T., Roller, A., Biehl, M., Fahrni, L., Nicolini, V., Perro, M., Nayak, T. K., Bommer, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650149 · Cited by 30
Sano, Y., Azuma, Y., Tsunenari, T., Kayukawa, Y., Shinozuka, J., Fujii, E., Amano, J., Nishito, Y., Maruyama, T., Kinoshita, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32952-3 · Cited by 27
Goekbuget, N., Stelljes, M., Viardot, A., et al. (2021) · Blood · doi:10.1182/blood-2021-146306 · Cited by 27
Kobayashi, T., Ubukawa, K., Fujishima, M., & Takahashi, N. (2021) · International Journal of Hematology · doi:10.1007/s12185-020-03047-w · Cited by 17
Zhang, H., Li, Y., Liu, X., Liang, Z., Yan, M., Liu, Q., Chen, A., Bao, Y., Zhou, C., Li, S., et al. (2018) · Immunology · doi:10.1111/imm.12954 · Cited by 13
McCall, D. C., Jabbour, E. J., Roth, M. E., Núnêz, C., & Cuglievan, B. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29939 · Cited by 12
Deppisch, N., Ruf, P., Eißler, N., Lindhofer, H., & Mocikat, R. (2016) · Oncotarget · doi:10.18632/oncotarget.13888 · Cited by 11
Schwartz, M. S., Jeyakumar, D., Damon, L. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps7064 · Cited by 10
Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future
Luskin, M. R., & DeAngelo, D. J. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(20)30458-4 · Cited by 6
Long, M., Williams, E., Berard, C., Cheney, C. M., Hu, E. Y., Bhat, S. A., Rogers, K. A., Woyach, J. A., Muthusamy, N., & Byrd, J. C. (2019) · Blood · doi:10.1182/blood-2019-125417 · Cited by 5
Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies
Cooper, S., & Brown, P. A. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-24424-8_8 · Cited by 4
Sánchez, J., Nicolini, V., Fahrni, L., Waldhauer, I., Walz, A., Jamois, C., Fowler, S. C., Simon, S., Klein, C., Umaña, P., et al. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00755-5 · Cited by 4
Nguyen, D., Jabbour, E. J., Short, N. J., Issa, G. C., Yilmaz, M. E., Daver, N. G., Pemmaraju, N., Chien, K. S., Masárová, L., Ravandi, F., et al. (2022) · Blood · doi:10.1182/blood-2022-167883 · Cited by 4
Haddad, F., Jabbour, E. J., Short, N. J., Jain, N., Huante, E. A., Sasaki, K., Nasnas, P. E., Ravandi, F., Kebriaei, P., Huang, X., et al. (2022) · Blood · doi:10.1182/blood-2022-170049 · Cited by 3
Hedvat, M., Zeng, V. G., Diaz, J. E., Bonzon, C., Avery, K. N., Rashid, R., Leung, I., Bartlow, N., Bakhit, C. G., Dragovich, M. A., et al. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0697 · Cited by 2
Research works printed but not linked: 1
- Litzow, 2022, Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network trial, LBA-1
Cited by
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Ash, L. J., Busia-Bourdain, O., Okpattah, D., Kamel, A., Liberchuk, A., & Wolfe, A. L. (2024) · Current Oncology · doi:10.3390/curroncol31040150 · Cited by 68
Racacho, K. J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621812 · Cited by 70
Innovative strategies for T cell engagers for cancer immunotherapy
Bergamaschi, C., Gaspar, M., Ciucci, T., Sitnikova, S. I., Cayatte, C., Pica, M., & Dovedi, S. J. (2025) · mAbs · doi:10.1080/19420862.2025.2531223 · Cited by 44
Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment
In, H., Park, M., Lee, H., & Han, K. H. (2025) · Antibodies · doi:10.3390/antib14010016 · Cited by 35
Hadidi, S. A., Heslop, H. E., Brenner, M. K., & Suzuki, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.039 · Cited by 30
Metadata
- Authors
- Zhu, W. M., & Middleton, M. R.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Zhu, Winston M
- Venue
- Immunotherapy Advances
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-01-01
- Volume
- 3
- Issue
- 1
- Pages
- ltad013-ltad013
- ISSN
- 2732-4303 (ISSN-L)
- PMC
- PMC10439528
- OpenAlex
- W4385713649
- Cited by
- 46
- References
- 115
- Citations by year
- 2026: 15 · 2025: 17 · 2024: 11 · 2023: 3
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Immunotherapy Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Roche
- AstraZeneca
- Novartis
- Millenium
- Immunocore
- Eisai
- Merck
- Rigontec
- BiolineRx
- Array Biopharma
- Pfizer
- Kineta
- Replimune
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- bispecific T-cell engagers, combination therapy, immune checkpoint, tumor microenvironment, T cell anergy, blinatumomab, immune checkpoint inhibitors, oncolytic viruses, costimulatory molecules, chemotherapy, solid tumors, cancer immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.